Rahi Tinni Basu

Rahi Tinni Basu

Auto-generated profile, based on publicly available information

Rahi Tinni Basu

Ohio State University 4 , Columbus, Ohio

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
LRLaxminarayan Rawat
Laxminarayan Rawat
CPChiranth M. Prakash
Chiranth M. Prakash
YSYuzuru Sasamoto
Yuzuru Sasamoto
RBRahi Tinni Basu
Rahi Tinni Basu
Akash SabarwalAkash Sabarwal
Akash Sabarwal
SPSoumitro Pal
Soumitro Pal
Acquired therapeutic resistance is a major problem in the treatment of advanced renal cell carcinoma (RCC). The receptor tyrosine kinase (RTK) c-Met is hyperactive in RCC and plays a major role in the survival of tumor cells during therapy-induced oxidative stress. Although the c-Met/RTK inhibitor cabozantinib (cabo) has demonstrated efficacy in the treatment of RCC, therapeutic resistance significantly restricts its effectiveness. Thus, new target molecules and combination therapies need to be explored. Among several cell-cycle regulators, Polo-like kinase 1 (PLK1), which is overexpressed in RCC, can play a vital role in cancer progression. In this study, for the first time, we show that the activation of c-Met markedly promotes renal cancer cell growth and proliferation through PLK1. We found that a novel combination treatment with cabo and a PLK1 inhibitor (onvansertib) induces dual-phase cell-cycle arrest at both G1 and G2–M checkpoints and impairs RCC cell migration. It induces tumor cell apoptosis by downregulating the antioxidant transcription factor/cytoprotective molecule Nrf2/heme oxygenase-1 and inducing oxidative stress. Our results also showed that onvansertib can downregulate ATP-binding cassette transporters that are involved in drug resistance, and it resensitizes cabo-resistant RCC cells to apoptotic cell death. We further confirmed the effectiveness of the combination treatment through 3D spheroid culture as well as tumor xenograft models of RCC. Following combination treatment, there was increased drug-induced cytotoxicity and markedly reduced tumor growth in vivo. Together, our preclinical study identifies that cabo + onvansertib is an effective combination treatment to overcome c-Met–induced therapeutic resistance in RCC with translational potential.